Table 1.
Characteristics of Subjects In Lymphocyte and Brain Samples
| Characteristic | Schizophrenia - CSZ | Control - NPC | Test |
|---|---|---|---|
| (A) LYMPHOCYTE SAMPLES | (n=60 −61) | (n= 49) | |
| Age (m) | 44.7± 9.7 | 35.6 ±10.8 | T=4.64, df=108, P=<0.001 |
| Sex (M/F) (n) | 52/9 | 33/16 | Χ2 4.96=, df=1 P=0.026 |
| Race (W/B/H/A) (n) | 17/39/3/2 | 13/32/2/2 | FET= 1.000 |
| Cigarette smoker (Y/N) (n) | 38/23 | 10/39 | Χ2 =19.38.df=1,P<0.001 |
| Cigarette smoked/wk (m) | 34.6 ±44.2 | 13.0± 28.7 | T=2.95, df=108,P=0.004 |
| Antipsychotic Treatment (lst Gen/2nd gen/combined (n) | 4/38/19 | NR | |
| On Clozapine (Y/N) (n) | 28/33 | NR | |
| On Antidepressant (Y/N/) (n) | 6/52 | 0/49 | |
| On Mood stabilizer (Y/N) (n) | 18/42 | 0/49 | |
| On Valproate (Y/N) (n) | 9/52 | 0/49 | |
| On Benzodiazepine (Y/N) (n) | 22/38 | 0/49 | |
| PANSS Total (m) | 72.0± 14.9 | NR | |
| Urine Tox THC (P/N) (n) | 1/25 | 5/28 | FET=0.22 |
| Urine Tox Cocaine (P/N) (n) | 0/28 | 1/34 | FET=1.00 |
| (B) BRAIN SAMPLES | CSZ (n=19) | NPC (n=26) | |
| Age (m) | 56.3± 18.4 | 57.6 ±18.1 | T=0.23,df=32,P=0.819 |
| Sex M/F (n) | 12/7 | 19/7 | χ2=0.504, df=1, P=0.478 |
| Age of Onset of Illness (m) | 22.6 ± 9.9 | NR | |
| Type of Antipsychotic (not on antipsychotic, 1st gen, 2nd gen, combined 1st and second gen) (n) |
6/7/5/1 | NR | |
| On Clozapine (Yes/No) (n) | 2/17 | NR | |
| On Haloperidol (Yes/No)(n) | 5/14 | NR | |
| On Valproate (Yes/No) (n) | 3/16 | NR | |
| On Mood Stabilizer (Yes/No) (n) | 4/15 | NR |
NR= not relevant; (n)=number of subjects, m= Mean ± S.D., (Y/N) = Yes/No. NR=Not relevant or not available (M/F) = male/female, Race/Ethnicity: W=Caucasian, B=black or African American H=Hispanic, A=Asian. Antipsychotic type: lst Generation antipsychotic, 2nd generation antipsychotic, combined lst and 2nd generation antipsychotic. Statistical tests: Χ2=chi-square, FET=Fishers’ Exact Test. T= t-test.